|
NanoLogix Inc. Announces Historical First in Energy Generation With
Bioreactor-Produced Hydrogen At Welch's. |
HUBBARD, Ohio, HUBBARD, Ohio, September 17 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX - News) a nano-biotechnology company announced it has achieved an historical event with the first onsite generation of electricity using hydrogen gas produced from
its bioreactor prototype facility at Welch Foods Inc., a Cooperative in Pennsylvania.
A 5.5 kW generator converted to run on hydrogen was utilized for the demonstration. The generator ran flawlessly on hydrogen gas produced by NanoLogix’s hydrogen bioreactor system and powered multiple strings of 100-watt light bulbs. “To the best of our knowledge, this is the first time in history that electricity has been generated anywhere onsite using hydrogen produced through the use of bacteria to digest waste”, said Harry Diz, Department Chair and Professor of Environmental Engineering at Gannon University and NanoLogix Bioreactor Development chief.
Video
Paul Zorzie, Welch’s Engineering Manager, stated, “Welch’s is happy to provide the site at which this groundbreaking research into generating alternative energy from waste is taking place. We look forward to the potential of building upon these developments to scale up and use this energy for our operation.”
Bret Barnhizer, Chairman and CEO of NanoLogix, stated, “We are delighted at the results of the work by Professor Diz and associates and anticipate potential upscaling of the Welch’s operation to commercial bioreactor status. The Welch’s development enabling conversion of sugar from their wastewater stream to produce hydrogen has contributed immeasurably to ongoing research and development for processing other types of waste streams. Linked to that development and following our business plan for expansion, in the spring of 2008 we intend to begin bioreactor construction at the Erie Wastewater Treatment Plant for the extraction of hydrogen from their protein-rich activated sludge waste stream.”
About
NanoLogix, Inc.
NanoLogix
is an industry innovator in the research, development, and commercialization
of nano-biotechnologies, applications and processes. The Company
has developed and owns or has rights to 31 patents related to
various medical technologies, 5 of which also have hydrogen-generation
aspects. In the past year the Company has filed an additional
28 patent applications for discoveries related to hydrogen bioreactors,
medical testing, and innovative medical treatments potentially
related to leukemia and sepsis. NanoLogix is presently operating
a hydrogen bioreactor at Welch's Food. NanoLogix-developed patents
are used to design and market diagnostic test kits for use in
early detection of the
bacteria present in infectious and noninfectious human diseases
such as tuberculosis, pneumonia, HIV/AIDS, cancer, and cystic
fibrosis. The company also owns a patent for the non-toxic induction
of apoptosis ('cell suicide') for the treatment of cancer. BioNanoChannel
is a Trademark of NanoLogix, Inc. For more information on the
Company, visit www.nanologixinc.com.
This
press release contains statements, which may constitute "forward-
looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange
Act of 1934, as amended by the Private Securities Litigation Reform
Act of 1995. Those statements include statements regarding the
intent, belief or current expectations of NanoLogix, Inc., and
members of its management as well as the assumptions on which
such
statements are based. Prospective investors are cautioned that
any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual
results may differ materially from those contemplated by such
forward-looking statements. The Company undertakes no obligation
to update or revise forward-looking statements to reflect changed
assumptions, the occurrence of unanticipated events or changes
to future operating results.
Contact:
Investor Relations
Bret Barnhizer, CEO
Telephone: 330-534-0800
E-mail:
Bret@nanologixinc.com
